Department of Error (DOI:10.1016/S0140-6736(08)60237-8);Effect of aprotinin on renal dysfunction in patients undergoing on-pump and off-pump cardiac surgery: a retrospective observational study

The Lancet

Volumn 371, Issue 9611, 2008, Pages 475-482

  Mouton, Ronelle ^a   Finch, David ^a   Davies, Ian ^a   Binks, Andrea ^a   Zacharowski, Kai ^a  

^a BRISTOL ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APROTININ; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; TRANEXAMIC ACID;

ADULT; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG EFFECT; DRUG SAFETY; HUMAN; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OBSERVATIONAL STUDY; OFF PUMP SURGERY; POSTOPERATIVE CARE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE;

EID: 38849097821     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)61444-0     Document Type: Erratum

References (50)

1. Medicines and Healthcare products Regulatory Agency. Aprotinin (Trasylol): suspension of UK marketing authorisations (licences) (Nov 29, 2007). http://www.mhra.gov.uk/home/idcplg?IdcService=SS_GET_PAGE&useSeconda ry=true&ssDocName=CON2033201&ssTargetNodeId=221 (accessed Dec 3, 2007).
2. US Food and Drug Administration. FDA requests marketing suspension of trasylol (Nov 5, 2007). http://www.fda.gov/bbs/topics/NEWS/2007/NEW01738.html (accessed Dec 3, 2007).
3. Royston D., Bidstrup B., Taylor K., and Sapsford R. Effect of aprotinin on need for blood transfusion after repeat open-heart surgery. Lancet 2 (1987) 1289-1291
4. van O., Jansen N., Bidstrup B., et al. Effects of aprotinin on hemostatic mechanisms during cardiopulmonary bypass. Ann Thorac Surg 44 (1987) 640-645
5. Alderman E., Levy J., Rich J., et al. Analyses of coronary graft patency after aprotinin use: results from the International Multicenter Aprotinin Graft Patency Experience (IMAGE) trial. J Thorac Cardiovasc Surg 116 (1998) 716-730
6. D'Ambra M., Akins C., Blackstone E., et al. Aprotinin in primary valve replacement and reconstruction: a multicenter, double-blind, placebo-controlled trial. J Thorac Cardiovasc Surg 112 (1996) 1081-1089
7. Levy J., Pifarre R., Schaff H., et al. A multicenter, double-blind, placebo-controlled trial of aprotinin for reducing blood loss and the requirement for donor-blood transfusion in patients undergoing repeat coronary artery bypass grafting. Circulation 92 (1995) 2236-2244
8. Young C., and Horton R. Putting clinical trials into context. Lancet 366 (2005) 107-108
9. Blauhut B., Gross C., Necek S., Doran J., Spath P., and Lundsgaard-Hansen P. Effects of high-dose aprotinin on blood loss, platelet function, fibrinolysis, complement, and renal function after cardiopulmonary bypass. J Thorac Cardiovasc Surg 101 (1991) 958-967
10. Cosgrove III D., Heric B., Lytle B., et al. Aprotinin therapy for reoperative myocardial revascularization: a placebo-controlled study. Ann Thorac Surg 54 (1992) 1031-1036
11. Sundt III T., Kouchoukos N., Saffitz J., Murphy S., Wareing T., and Stahl D. Renal dysfunction and intravascular coagulation with aprotinin and hypothermic circulatory arrest. Ann Thorac Surg 55 (1993) 1418-1424
12. Westaby S., Forni A., Dunning J., et al. Aprotinin and bleeding in profoundly hypothermic perfusion. Eur J Cardiothorac Surg 8 (1994) 82-86
13. Karkouti K., Beattie W., Dattilo K., et al. A propensity score case-control comparison of aprotinin and tranexamic acid in high-transfusion-risk cardiac surgery. Transfusion 46 (2006) 327-338
14. Mangano D., Tudor I., and Dietzel C. The risk associated with aprotinin in cardiac surgery. N Engl J Med 354 (2006) 353-365
15. Henry D., Moxey A., Carless P., et al. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 4 (2007) CD001886.
16. Royston D., Levy J., Fitch J., et al. Full-dose aprotinin use in coronary artery bypass graft surgery: an analysis of perioperative pharmacotherapy and patient outcomes. Anesth Analg 103 (2006) 1082-1088
17. Sedrakyan A., Treasure T., and Elefteriades J. Effect of aprotinin on clinical outcomes in coronary artery bypass graft surgery: a systematic review and meta-analysis of randomized clinical trials. J Thorac Cardiovasc Surg 128 (2004) 442-448
18. Furnary A., Wu Y., Hiratzka L., Grunkemeier G., and Page III U. Aprotinin does not increase the risk of renal failure in cardiac surgery patients. Circulation 116 suppl 11 (2007) I127-I133
19. Hogue C., and London M. Aprotinin use during cardiac surgery: a new or continuing controversy?. Anesth Analg 103 (2006) 1067-1070
20. Myers B., and Moran S. Hemodynamically mediated acute renal failure. N Engl J Med 314 (1986) 97-105
21. Sear J. Kidney dysfunction in the postoperative period. Br J Anaesth 95 (2005) 20-32
22. Chertow G., Lazarus J., Christiansen C., et al. Preoperative renal risk stratification. Circulation 95 (1997) 878-884
23. Conlon P., Stafford-Smith M., White W., et al. Acute renal failure following cardiac surgery. Nephrol Dial Transplant 14 (1999) 1158-1162
24. Godet G., Fleron M., Vicaut E., et al. Risk factors for acute postoperative renal failure in thoracic or thoracoabdominal aortic surgery: a prospective study. Anesth Analg 85 (1997) 1227-1232
25. Tuttle K., Worrall N., Dahlstrom L., Nandagopal R., Kausz A., and Davis C. Predictors of ARF after cardiac surgical procedures. Am J Kidney Dis 41 (2003) 76-83
26. Ascione R., Lloyd C., Underwood M., Gomes W., and Angelini G. On-pump versus off-pump coronary revascularization: evaluation of renal function. Ann Thorac Surg 68 (1999) 493-498
27. Ascione R., Nason G., Al-Ruzzeh S., Ko C., Ciulli F., and Angelini G. Coronary revascularization with or without cardiopulmonary bypass in patients with preoperative nondialysis-dependent renal insufficiency. Ann Thorac Surg 72 (2001) 2020-2025
28. Textor S. Renal failure related to angiotensin-converting enzyme inhibitors. Semin Nephrol 17 (1997) 67-76
29. Horl W. Aprotinin and renal function in patients undergoing cardiac surgery. Br J Anaesth 84 (2000) 3-5
30. Waxler B., and Rabito S. Aprotinin: a serine protease inhibitor with therapeutic actions: its interaction with ACE inhibitors. Curr Pharm Des 9 (2003) 777-787
31. Khan N., De S., Mister R., et al. A randomized comparison of off-pump and on-pump multivessel coronary-artery bypass surgery. N Engl J Med 350 (2004) 21-28
32. Watters M., Ascione R., Ryder I., Ciulli F., Pitsis A., and Angelini G. Haemodynamic changes during beating heart coronary surgery with the 'Bristol Technique'. Eur J Cardiothorac Surg 19 (2001) 34-40
33. Royston D. High-dose aprotinin therapy: a review of the first five years' experience. J Cardiothorac Vasc Anesth 6 (1992) 76-100
34. D'Agostino Jr. R. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 17 (1998) 2265-2281
35. Rosenbaum P., and Rubin D. The central role of the propensity score in observational studies for causal effects. Biometrika 70 (1983) 41-55
36. Rosenbaum P., and Rubin D. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc 79 (1984) 516-524
37. Dietrich W., Busley R., and Kriner M. High-dose aprotinin in cardiac surgery: is high-dose high enough? An analysis of 8281 cardiac surgical patients treated with aprotinin. Anesth Analg 103 (2006) 1074-1081
38. Kapetanakis E., Medlam D., Petro K., et al. Effect of clopidogrel premedication in off-pump cardiac surgery-are we forfeiting the benefits of reduced hemorrhagic sequelae?. Circulation 113 (2006) 1667-1674
39. van der Linden J., Lindvall G., and Sartipy U. Aprotinin decreases postoperative bleeding and number of transfusions in patients on clopidogrel undergoing coronary artery bypass graft surgery-a double-blind, placebo-controlled, randomized clinical trial. Circulation 112 (2005) I276-I280
40. Kincaid E., Ashburn D., Hoyle J., Reichert M., Hammon J., and Kon N. Does the combination of aprotinin and angiotensin-converting enzyme inhibitor cause renal failure after cardiac surgery?. Ann Thorac Surg 80 (2005) 1388-1393
41. Mannucci P. Hemostatic drugs. N Engl J Med 339 (1998) 245-253
42. Soslau G., Horrow J., and Brodsky I. Effect of tranexamic acid on platelet ADP during extracorporeal circulation. Am J Hematol 38 (1991) 113-119
43. Brown J., Birkmeyer N., and O'Connor G. Meta-analysis comparing the effectiveness and adverse outcomes of antifibrinolytic agents in cardiac surgery. Circulation 115 (2007) 2801-2813
44. O'Connor C., Brown D., Avramov M., Barnes S., O'Connor H., and Tuman K. The impact of renal dysfunction on aprotinin pharmacokinetics during cardiopulmonary bypass. Anesth Analg 89 (1999) 1101-1107
45. Feindt P., Walcher S., Volkmer I., et al. Effects of high-dose aprotinin on renal function in aortocoronary bypass grafting. Ann Thorac Surg 60 (1995) 1076-1080
46. Lemmer Jr. J., Stanford W., Bonney S., et al. Aprotinin for coronary artery bypass grafting: effect on postoperative renal function. Ann Thorac Surg 59 (1995) 132-136
47. Schweizer A., Hohn L., Morel D., Kalangos A., and Licker M. Aprotinin does not impair renal haemodynamics and function after cardiac surgery. Br J Anaesth 84 (2000) 16-22
48. Bellomo R., Ronco C., Kellum J., Mehta R., and Palevsky P. Acute renal failure-definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 8 (2004) R204-R212
49. Bellomo R., Kellum J., and Ronco C. Defining and classifying acute renal failure: from advocacy to consensus and validation of the RIFLE criteria. Intensive Care Med 33 (2007) 409-413
50. Keogh B., and Kinsman R. Fifth national adult cardiac surgical database report 2003 (2004), Dendrite Clinical Systems, Henley on Thames